Get the right drug to the right patient population
Fill in the form to watch our presentation
Personalized medicine holds great promise for the future of patient treatment, offering the opportunity to refine our understanding of risk/benefits of a new treatment and identify subsets of patients that are more likely to respond based on pharmacogenomic data.
HUB Organoids™ have contributed to recent approvals of a new drug to treat cystic fibrosis based on a personalized medicine approach and are actively supporting preclinical precision medicine programs in several other therapeutic areas.
In this presentation Dr. Rob Vries, CEO:
- Describes current progress in the field of personalized medicine
- Reviews data on HUB Organoids™ applications as powerful tools to predict patient response
- Identifies outstanding challenges such as new trial designs in personalized medicine
- Discusses what evidences may still be needed for the approval of organoids as in vitro diagnostic tools